AHCC Extract which Potentially Can Attenuate Immunological Toxicity in Patients with Neuroendocrine Tumors after Treatment with the Radioisotope Preparation (90Y-DOTA-TATE): An Initial Report Abstract #989

Introduction: Active hexose correlated compound (AHCC) is an alfa-glucan nutritional supplement made from the mycelia of Lentinula edodes mushroom. Human clinical studies have shown that AHCC significantly improves immune response, increases normal NK cell activity and enhances macrophage and T‑cell activity.
Aim(s): To assess the efficacy of AHCC to protect the immunological system in neuroendocrine tumor (NET) patients after 90Y-DOTA-TATE therapy.
Materials and methods: We evaluated three patients with confirmed NETs. Patients were treated with four doses of 90Y-DOTA-TATE (3.7 GBq/m2 /dose) in 8-10 week intervals (median dose 14,8 Gbq/m2 per patient). Control computed tomography and PET/CT with somatostatin analog 68Ga-DOTA-TATE were conducted three months after the last dose of 90Y-DOTA-TATE. Patients took AHCC in the amount of 3 × 2 g daily, 40 min before meals. Immunological toxicity has been compared with nine patients summarised by Sierra study. In the Italian group, the average dose of 90Y-DOTA-TOC was 5.5 GBq per patient.
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: PhD Norbert Szaluś
Keywords: AHCC, NET, PRRT

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1505 A Blood-Based Multi-Transcript Test, the NETest, Predicts and Defines PRRT Efficacy in Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Mark Kidd
Authors: Bodei L, Kidd M, Severi S, Drozdov I, ...
Keywords: NETest, PRRT
#889 Delayed Haematological Toxicity in Patients Treated with 177Lu-octreotate Peptide Receptor Radiotherapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs)
Introduction: PRRT is associated with a high tumor control rate and early toxicity seems acceptable (haematological grade 3-4 toxicity: 11.3%). Long-term monitoring of haematological toxicity is unavailable.
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Olivia Hentic
#1228 Measurement of Blood Gene Transcripts Defines PRRT Therapeutic Efficacy
Introduction: PRRT is an effective therapy for NETs since the majority over-express SSRs. Typically, well or moderately differentiated NETs (G1/G2) are treated. Imaging and CgA are used to evaluate response but both RECIST criteria and CgA have limitations.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Bodei L, Paganelli G, Kidd M, Severi S, ...
#1879 A Hybrid Clinical Molecular Nomogram Accurately Predicts Survival in PRRT Treated GEP-NETs
Introduction: Clinical assessment has limited prognostic ability. Mathematical tools –nomograms- that incorporate multiple parameters are more effective. Novel transcriptomic data has added value in defining NET biology in tissue and blood. A blood multigene expression analysis test is effective as a molecular prognostic marker for PFS.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Professor Mark Kidd
Authors: Kidd M, Bodei L, Severi S, Drozdov I, ...
#101 Chronic Complications of Peptide Receptor Radionuclide Therapy (PRRT)- A Single Center Experience
Introduction: In the last decade, a new treatment modality, peptide receptor radionuclide therapy (PPRT), has been introduced for gastroenteropancreatic neuroendocrine tumor (GEPNET) patients with non-resectable or progressive disease. PRRT has been associated with several complications, including bone marrow suppression, renal toxicity and hepatic damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Merav Fraenkel
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.